Drug Search Results
More Filters [+]

SMP-3124

Alternative Names: SMP-3124, SMP 3124, SMP3124
Latest Update: 2024-08-09
Latest Update Note: Clinical Trial Update

Product Description

SMP-3124 is an injection, a liposomally encapsulated CHK1 (checkpoint kinase 1) inhibitor. CHK1 is activated by DNA damage response, then arrests the cell cycle, and induces DNA repair via serine-threonine kinase. CHK1 inhibition leads cancer cell with high replication stress to apoptosis by inducing further DNA damages. SMP-3124 is expected to strengthen the anti-tumor activity and weaken side effects by changing pharmacokinetics of the compound with liposomal nanomedicinal encapsulation. (Sourced from: https://www.sumitomo-pharma.com/rd/pipeline_new-medicine/pipeline_profile.html)

Mechanisms of Action: CHK1 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sumitomo Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for SMP-3124

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title